Far more than most people do — roughly 250–500 g per week for an adult with widespread involvement, at least twice daily and always after bathing.

Although the exact mechanism of eczema triggers is not fully understood, some known environmental factors can be stressful for eczema, such as exposure to high temperatures, contact with chemicals, and skin trauma (e.g., tattoos, eyebrow treatments, laser whitening, chemical peels, etc.). These should be avoided.

Because inflammation persists beneath skin that looks better, and because reactive treatment alone does not prevent the next flare. Proactive maintenance — a topical anti-inflammatory twice weekly to sites that usually flare — roughly halves flare frequency.

Yes. Narrowband UVB is well established for moderate disease not controlled by topical treatment. It reduces itch and inflammation and allows topical steroid use to be reduced. It usually requires two to three sessions weekly for 8–12 weeks.

The pathogenesis and triggers of eczema are not yet fully understood, involving genetic and environmental factors. Even among family members with similar genetics, they do not experience the same environmental exposures, contact with chemicals, skin trauma, emotional events, or environmental stress. Medical assessment and clinical treatment are crucial for managing eczema. Beauty treatments that lack clinical medical recognition and involve misuse or overuse of optical devices, or the use of undocumented remedies, can lead to unpredictable progression or worsening of eczema, and even trigger complications. For medical treatment of eczema, it is advised to seek assistance from a registered doctor.

Biologics are injections that block a single inflammatory signal. Approved options include dupilumab, tralokinumab, lebrikizumab and nemolizumab. They are for moderate-to-severe disease not controlled by topical treatment and phototherapy, and they do not require routine blood monitoring.

Oral JAK inhibitors have shown high efficacy with rapid itch reduction and significant skin clearance in phase 3 trials. They require blood monitoring and carry class warnings relating to infection, blood count and lipid changes, and cardiovascular risk in older patients with risk factors. Suitability depends on age, medical history and disease severity, and should be discussed individually.

Neither is universally better. Abrocitinib and upadacitinib have shown superior efficacy to dupilumab in clinical studies, and act faster — but they require monitoring and carry class warnings that biologics do not. Younger patients wanting rapid control often favour JAK inhibitors; older patients or those with cardiovascular risk factors usually favour a biologic.

This is post-inflammatory hyperpigmentation, which is more prominent in Asian skin. It is not scarring, it fades over months, and it improves by controlling the inflammation rather than by using lightening products.

The appearance of eczema patches and flaking skin not only causes great mental distress to children and adolescents but also leads to peer exclusion/bullying; it equally causes great pain and guilt for parents. Parents are advised to first manage their emotions, understanding that the condition is unavoidable, and seek medical help for their child as early as possible to learn how to soothe eczema and effectively improve it in daily life. Once a treatment plan is established by a doctor, it is recommended that parents and schools communicate as much as possible, instill correct and positive values, maintain an optimistic and proactive attitude, and patiently adhere to medical treatment. At the same time, parents can refer to examples of other people with eczema to encourage and rebuild self-confidence and self-care.

Eczema should be clinically diagnosed and treated by a registered doctor. Many patients have a family history or involve multiple genetic mutations, and may also share genetic mutations with other autoimmune diseases; doctors will first inquire about the patient's and family's medical history and also establish if the patient has any other autoimmune diseases. Medical Assessment